We estimated EGFR mutational expression (including all mutations from exon 18 to 21) and ALK rearrangement on 10 (34%) metastatic effusions in NSCLC, and 7 KRAS genes in intestinal metastatic peritoneal carcinomas. This evidence concerns the gene EGFR and non-small cell lung carcinoma.